NASDAQ:NPSP - Shire-Nps Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market Capitalization$4.99 billion
P/E RatioN/A
Dividend YieldN/A

About Shire-Nps Pharmaceuticals (NASDAQ:NPSP)

Shire-Nps Pharmaceuticals logoNPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company's primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company's second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.

Receive NPSP News and Ratings via Email

Sign-up to receive the latest news and ratings for NPSP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-2.96%
Return on Equity-5.98%
Return on Assets-2.77%


Outstanding SharesN/A

Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Frequently Asked Questions

What is Shire-Nps Pharmaceuticals' stock symbol?

Shire-Nps Pharmaceuticals trades on the NASDAQ under the ticker symbol "NPSP."

How were Shire-Nps Pharmaceuticals' earnings last quarter?

Shire-Nps Pharmaceuticals Inc (NASDAQ:NPSP) announced its quarterly earnings results on Wednesday, February, 18th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by $0.08. The biopharmaceutical company had revenue of $66.70 million for the quarter, compared to analysts' expectations of $69.30 million. Shire-Nps Pharmaceuticals had a negative net margin of 2.96% and a negative return on equity of 5.98%. View Shire-Nps Pharmaceuticals' Earnings History.

Has Shire-Nps Pharmaceuticals been receiving favorable news coverage?

News headlines about NPSP stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Shire-Nps Pharmaceuticals earned a news impact score of 0.21 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 47.67 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Shire-Nps Pharmaceuticals?

Shares of NPSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How big of a company is Shire-Nps Pharmaceuticals?

Shire-Nps Pharmaceuticals has a market capitalization of $4.99 billion.

How can I contact Shire-Nps Pharmaceuticals?

Shire-Nps Pharmaceuticals' mailing address is 550 Hills Dr, BEDMINSTER, NJ 07921-1537, United States. The biopharmaceutical company can be reached via phone at +1-908-4505300.

MarketBeat Community Rating for Shire-Nps Pharmaceuticals (NPSP)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  375
MarketBeat's community ratings are surveys of what our community members think about Shire-Nps Pharmaceuticals and other stocks. Vote "Outperform" if you believe NPSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NPSP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/24/2016 forward)


Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Earnings History and Estimates Chart

Earnings by Quarter for Shire-Nps Pharmaceuticals (NASDAQ:NPSP)

Shire-Nps Pharmaceuticals (NASDAQ NPSP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/18/2015Q414$0.06($0.02)$69.30 million$66.70 millionViewN/AView Earnings Details
11/10/2014Q314$0.01($0.02)$59.50 million$57.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.01)$0.02$53.06 million$56.10 millionViewListenView Earnings Details
5/8/2014Q114($0.04)($0.06)$48.30 million$44.04 millionViewListenView Earnings Details
2/18/2014Q413$0.02$0.07$44.22 million$54.45 millionViewListenView Earnings Details
11/6/2013Q3 2013($0.02)($0.01)$37.59 million$39.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.07)($0.13)$31.62 million$36.50 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.13)($0.09)$27.56 million$25.43 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.09)($0.14)$28.93 million$27.10 millionViewListenView Earnings Details
11/9/2012Q312($0.16)($0.04)$28.18 million$27.02 millionViewN/AView Earnings Details
8/1/2012($0.09)$0.08ViewN/AView Earnings Details
5/3/2012($0.11)($0.12)ViewN/AView Earnings Details
2/15/2012($0.11)($0.10)ViewN/AView Earnings Details
11/3/2011($0.10)($0.14)ViewN/AView Earnings Details
8/2/2011($0.07)($0.07)ViewN/AView Earnings Details
5/3/2011($0.12)($0.13)ViewN/AView Earnings Details
2/15/2011($0.20)($0.09)ViewN/AView Earnings Details
11/2/2010Q3 2010($0.18)($0.26)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.15)($0.11)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.21)($0.14)ViewN/AView Earnings Details
3/11/2010Q4 2009($0.12)($0.17)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.12)($0.16)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.25)$0.05ViewN/AView Earnings Details
5/5/2009Q1 2009($0.26)($0.22)ViewN/AView Earnings Details
3/13/2009Q4 2008($0.11)($0.05)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.05)($0.01)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.17)$0.03ViewN/AView Earnings Details
5/7/2008Q1 2008($0.13)($0.28)ViewN/AView Earnings Details
3/13/2008Q4 2007$0.20$0.40ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Shire-Nps Pharmaceuticals (NASDAQ NPSP) Insider Trading and Institutional Ownership History

Insider Trading History for Shire-Nps Pharmaceuticals (NASDAQ:NPSP)

Shire-Nps Pharmaceuticals (NASDAQ NPSP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/10/2015Susan E GrafVPSell6,711$45.87$307,833.57View SEC Filing  
12/17/2014Joseph J RogusSVPSell16,467$35.00$576,345.00View SEC Filing  
12/17/2014Luke M BesharCFOSell52,258$35.00$1,829,030.00View SEC Filing  
12/17/2014Rachel R SeliskerDirectorSell3,708$34.59$128,259.72View SEC Filing  
12/8/2014Rachel R SeliskerDirectorSell23,157$34.50$798,916.50View SEC Filing  
11/28/2014Rachel R SeliskerDirectorSell11,635$34.50$401,407.50View SEC Filing  
11/17/2014Joseph J RogusSVPSell26,782$30.00$803,460.00View SEC Filing  
11/11/2014Rachel R SeliskerDirectorSell15,188$29.50$448,046.00View SEC Filing  
10/31/2014Luke M BesharCFOSell10,000$29.00$290,000.00View SEC Filing  
10/27/2014Luke M BesharCFOSell30,635$26.75$819,486.25View SEC Filing  
2/13/2014Georges GemayelDirectorSell6,188$37.70$233,287.609,000View SEC Filing  
1/8/2014Luke BesharCFOSell31,588$35.01$1,105,895.8859,180View SEC Filing  
12/26/2013Luke BesharCFOSell37,874$30.02$1,136,977.4859,180View SEC Filing  
12/23/2013James GroningerDirectorSell3,000$29.50$88,500.00750View SEC Filing  
12/18/2013Ed StratemeierSVPSell205,432$25.13$5,162,506.1642,339View SEC Filing  
9/20/2013Luke BesharCFOSell50,000$30.26$1,513,000.0059,180View SEC Filing  
9/16/2013Joseph RogusVPSell25,312$28.11$711,520.3219,372View SEC Filing  
9/16/2013Luke BesharCFOSell50,000$27.89$1,394,500.0059,180View SEC Filing  
8/30/2013Roger GarceauCMOSell110,000$25.18$2,769,800.0064,146View SEC Filing  
8/20/2013James GroningerDirectorSell16,900$23.21$392,249.00750View SEC Filing  
5/9/2013Luke M BesharCFOSell45,150$14.18$640,227.00View SEC Filing  
11/15/2012Glenn R MelroseSVPBuy11,000$9.09$99,990.00View SEC Filing  
10/3/2012Roger GarceauCMOSell140,625$9.51$1,337,343.75View SEC Filing  
(Data available from 1/1/2013 forward)


Shire-Nps Pharmaceuticals (NASDAQ NPSP) News Headlines

Financial Review: Shire-Nps Pharmaceuticals (NPSP) & Heat Biologics (HTBX)Financial Review: Shire-Nps Pharmaceuticals (NPSP) & Heat Biologics (HTBX) - January 11 at 9:50 PM
Dicerna Announces Appointment of Ralf Rosskamp, M.D., as Chief Medical OfficerDicerna Announces Appointment of Ralf Rosskamp, M.D., as Chief Medical Officer - June 8 at 9:48 AM
Syndax Pharmaceuticals (SNDX) Names Pierre Legault to Board of DirectorsSyndax Pharmaceuticals (SNDX) Names Pierre Legault to Board of Directors - January 6 at 2:13 AM
Syndax Adds Global Pharmaceutical Business Veteran to Board of DirectorsSyndax Adds Global Pharmaceutical Business Veteran to Board of Directors - January 5 at 9:02 PM
Shire (SHPG) Gets EU Nod for Label Expansion of RevestiveShire (SHPG) Gets EU Nod for Label Expansion of Revestive - July 8 at 6:34 PM
A Deep Dive Into Shires Business - Seeking AlphaA Deep Dive Into Shire's Business - Seeking Alpha - May 30 at 4:40 PM
Company Overview of NPS Pharmaceuticals, Inc.Company Overview of NPS Pharmaceuticals, Inc. - April 11 at 10:07 PM
Smart-Money Healthcare Investing Focuses On Major Biotech Stocks - Seeking AlphaSmart-Money Healthcare Investing Focuses On Major Biotech Stocks - Seeking Alpha - March 28 at 4:33 PM
NPS Pharmaceuticals, Inc. Company ProfileNPS Pharmaceuticals, Inc. Company Profile - February 25 at 4:46 PM
Shire Fourth-Quarter Earnings Exceed Analysts ExpectationShire Fourth-Quarter Earnings Exceed Analysts' Expectation - February 11 at 9:02 AM
Shire target NPS Pharma wins FDA approval for NatparaShire target NPS Pharma wins FDA approval for Natpara - January 26 at 3:43 AM
Shire shares jump as drug approval vindicates $5.2 bln NPS purchaseShire shares jump as drug approval vindicates $5.2 bln NPS purchase - January 26 at 3:16 AM
U.S. FDA approves NPS drug, in move validating Shire takeover dealU.S. FDA approves NPS drug, in move validating Shire takeover deal - January 23 at 7:39 PM
[video]Jim Cramers Mad Money Recap: Blame Tech, Oil and Retail for Todays Losses[video]Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses - January 12 at 8:32 PM
Shire acquires US rival NPS Pharmaceuticals for $5.2bnShire acquires US rival NPS Pharmaceuticals for $5.2bn - January 12 at 8:18 AM
NPS a "natural fit" for pharma group Shire, says UBSNPS a "natural fit" for pharma group Shire, says UBS - January 12 at 6:21 AM

SEC Filings

Shire-Nps Pharmaceuticals (NASDAQ:NPSP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Income Statement, Balance Sheet and Cash Flow Statement


Shire-Nps Pharmaceuticals (NASDAQ NPSP) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.